The EVP, Chief Strat & Port. Off. of Alexion Pharmaceuticals is Selling Shares

By George MacDonald

Yesterday, the EVP, Chief Strat & Port. Off. of Alexion Pharmaceuticals, Saqib Islam, sold stocks of ALXN for $1.1M.

In addition to Islam, one other ALXN executives reported Sell trades in the last month.

Based on Alexion Pharmaceuticals` latest earnings report from March 31, the company posted quarterly revenue of $600.3M and quarterly net profit of $91.32M. In comparison, last year the company earned revenue of $566.6M and had a net profit of $159.4M. The company has a one year high of $$203.30 and a one year low of $$147.81. ALXN’s market cap is $34.65B and the company has a P/E ratio of 59.4%.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $223.50, reflecting a -24.3% downside.

Looking at blogger coverage of ALXN, there is a 90% Bullish tendency on the stock, in relation to a 69% average bullish tendency within the Healthcare sector.

Over the last 3 months, the insider sentiment on Alexion Pharmaceuticals has been negative based on 103 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.